Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
br Introduction Thrombosis is one of the
2021-10-21

Introduction Thrombosis is one of the leading causes of deaths in the cardiovascular diseases such as myocardial infarction (MI), unstable Flufenamic acid and acute coronary syndrome (ACS) in developed countries [1], [2]. It is estimated that venous thromboembolism (VTE) afflicts about 1 million
-
Two US FDA approved assays are commonly
2021-10-21

Two US FDA-approved assays are commonly used for VL monitoring: the COBAS AmpliPrep/COBAS® Taqman® HIV-1 version 2.0 (“CAP/CTM HIV-1 v2”; Roche Molecular Systems) [18], and the RealTime HIV-1 assay (“RealTime HIV-1”, Abbott Molecular) [19]. Several studies have shown good correlation between the ass
-
br Conclusion The hub gene KIBRA
2021-10-21

Conclusion The hub gene KIBRA and the Hippo signaling pathway were downregulated and miR-21 was upregulated in LAD. MiR-21 promoted the viability and mobility of LAD cells, reduced apoptosis and suppressed the Hippo signaling pathway in LAD through targeting KIBRA. Funding The study was appro
-
In this study we present the first data on the
2021-10-21

In this study, we present the first data on the kinetic properties of the hexokinase of T. equiperdum, which we compare with similar data available for pleomorphic T. brucei (Seed and Baquero, 1965, Nwagwu and Opperdoes, 1982, Hara et al., 1997, Morris et al., 2006, Chambers et al., 2008b, Chambers
-
The glycine receptor is an ionotropic neurotransmitter
2021-10-21

The glycine receptor is an ionotropic neurotransmitter receptor coupled to a chloride ion channel. Glycine receptors are typically described as inhibitory and distributed in the spinal cord and brainstem, though mRNA transcription labelling studies in rats show expression in the hippocampus, cingula
-
br Acknowledgements br Introduction High intensity noise exp
2021-10-21

Acknowledgements Introduction High-intensity noise exposure has long been known to induce damage in the peripheral and central auditory system, often resulting in auditory pathologies such as hearing loss, tinnitus and hyperacusis (Syka, 2002; Roberts et al., 2010). Within the inner ear, struc
-
GLP and glucose dependent insulinotropic
2021-10-21

GLP-1 and glucose-dependent insulinotropic peptide (GIP) are gut hormones secreted from intestinal L akt inhibitors and K cells, respectively. Together, these hormones account for the vast majority of the incretin effect, the enhanced postprandial insulin secretion observed in healthy adults (Dupre
-
br Introduction Farnesoid X receptor FXR is a bile acid
2021-10-21

Introduction Farnesoid X receptor (FXR) is a bile Quinacrine hydrochloride hydrate regulated nuclear receptor highly expressed in the liver, intestine, kidney and adrenal glands in rodents.1, 2, 3, 4 FXR regulates transport proteins, the bile salt export pump (BSEP) and the organic solute transp
-
br Modulators of the GUCY C cGMP PDEs
2021-10-20

Modulators of the GUCY2C/cGMP/PDEs signaling pathways for CRC prevention and therapy (pre-clinical and clinical development) Several modulators of the GUCY2C/cGMP/PDEs signaling pathways, including GUCY2C agonists and PDEs inhibitors, have been developed and explored as chemopreventive agents for
-
In conclusion this is the first description of
2021-10-20

In conclusion, this is the first description of a GPR81 agonist with an ability to exert in vivo efficacy without causing flushing. These results demonstrate that GPR81 small-molecule agonists may be effective for treating dyslipidemia. In addition, targeting GPR81 could prevent the unwanted side ef
-
The first described synthetic FFA
2021-10-20

The first described synthetic FFA1 active agonist, GW9508 (4- [(3-phenoxyphenyl)methyl]amino benzenepropanoic acid), was immediately shown to also activate FFA4, although with some 100-fold lower potency [38]. Therefore, in the initial absence of FFA4-selective synthetic agonist ligands, GW9508 was
-
In contrast with the above
2021-10-20

In 412 2 with the above results, in our GC model system, FPR1-, but not FPR2-knockout, enhanced tumour formation. However, it should be noted that the prominent role of mFPR2 with respect to mFPR1 in the mouse colon might be due to the significantly higher expression of mFPR2 than mFPR1 in this tis
-
br Introduction Stroke is the
2021-10-20

Introduction Stroke is the second cause of death worldwide and the first cause of acquired motor disability in adults [1], [2]. In sub-Saharan Africa, stroke is the first cause of admission in neurology departments [3]. In Cameroon, the in-hospital mortality of stroke is estimated at 26.8% [4]. A
-
Second although HO expression in the stromal macrophages has
2021-10-20

Second, although HO-1 expression in the stromal macrophages has been seen in the other cancer tissues [21], the impact of HO-1 expression on EAOC progression has not been explored. We have found that the CD163+ M2-like sr9009 mg were HO-1+ in OE, but malignant transformation may be associated with,
-
Compound containing dimethylglutarimide P cap P propyl group
2021-10-20

Compound containing, dimethylglutarimide P-cap, P propyl group, α-methylbenzyl urea resulted in inhibitor with much improved binding (=0.064μM) and EC=0.3μM. This was an aza-peptide analog with an EC comparable to our first generation clinical candidate . Analog was evaluated for its selectivity aga
15306 records 590/1021 page Previous Next First page 上5页 586587588589590 下5页 Last page